中国生物制药尾盘涨超10%,因预期重磅BD交易和创新药增长。默沙东将收购维罗纳制药,估值约100亿美元。中生制药预计未来几年有多款创新药获批,助力增长。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.